These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30350561)

  • 21. Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective.
    Bi Y; Liu J; Wang J; Epps RE; Kettl D; Marcus K; Seo S; Zhu H; Wang Y
    AAPS J; 2019 Jul; 21(5):91. PubMed ID: 31325056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
    Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
    Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab dose intensification in hidradenitis suppurativa: effectiveness and safety results of a multicentre study.
    Sánchez Martínez EM; Murray G; Alfageme Roldán F; García Ruiz R; Tobin AM; Zouboulis CC
    Br J Dermatol; 2021 Oct; 185(4):863-865. PubMed ID: 34050921
    [No Abstract]   [Full Text] [Related]  

  • 24. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
    Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE
    J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
    Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
    J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
    Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
    Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
    Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
    J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Carroll C; Stevens JW; Rawdin A; Grimm S; Clowes M; Kaltenthaler E; Ingram JR; Collier F; Ghazavi M
    Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can Adalimumab Reduce the Extent of Hidradenitis Suppurativa Surgery?
    Guillem P; Perat C; Vlaeminck-Guillem V
    JAMA Surg; 2022 Jun; 157(6):552-553. PubMed ID: 35262636
    [No Abstract]   [Full Text] [Related]  

  • 31. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.
    Porter ML; Golbari NM; Lockwood SJ; Kimball AB
    Semin Cutan Med Surg; 2018 Sep; 37(3):182-189. PubMed ID: 30215636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
    Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
    Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease.
    Moyano B; Clemente A; Marín-Jiménez I; Martorell A
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():43-50. PubMed ID: 28081769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of patients with hidradenitis suppurativa.
    Martorell A; Caballero A; González Lama Y; Jiménez-Gallo D; Lázaro Serrano M; Miranda J; Pascual JC; Salgado-Boquete L; Marín-Jiménez I
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():32-42. PubMed ID: 28081768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic.
    Benesh G; Andriano TM; Babbush KM; Hosgood HD; Cohen SR
    J Cutan Med Surg; 2021; 25(4):446-448. PubMed ID: 33625899
    [No Abstract]   [Full Text] [Related]  

  • 37. Squamous cell carcinoma of the cervix arising in a patient on adalimumab � a need for cervical screenings in patients on tumor necrosis factor inhibitors.
    Bessaleli E; Scheinfeld N; Kroumpouzos- G
    Dermatol Online J; 2018 May; 24(5):. PubMed ID: 30142745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of hidradenitis suppurativa with biologic medications.
    Lee RA; Eisen DB
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.
    Nader A; Beck D; Noertersheuser P; Williams D; Mostafa N
    Clin Pharmacokinet; 2017 Sep; 56(9):1091-1102. PubMed ID: 28066879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
    Arenbergerova M; Gkalpakiotis S; Arenberger P
    Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.